Costs of congenital rubella syndrome (CRS) in Oman: Evidence based on long-term follow-up of 43 children.


Al-Awaidy, S; Griffiths, UK; Nwar, HM; Bawikar, S; Al-Aisiri, MS; Khandekar, R; Mohammad, AJ; Robertson, SE; (2006) Costs of congenital rubella syndrome (CRS) in Oman: Evidence based on long-term follow-up of 43 children. Vaccine, 24 (40-41). pp. 6437-45. ISSN 0264-410X DOI: 10.1016/j.vaccine.2006.05.089

Full text not available from this repository.

Abstract

As part of the national plan for elimination of rubella and congenital rubella syndrome (CRS), Oman established a national registry of CRS cases. As of May 2005, the registry included 43 surviving CRS cases, with a mean age of 11.9 years. Clinical examinations found that 84% had ocular defects, 84% had auditory/speech defects, 70% had neurological manifestations, and 42% had cardiac defects. Lifetime medical, special education, and rehabilitation costs were assessed. Using a discount rate of 3%, the average direct lifetime cost per surviving CRS patient was estimated at US$ 18,644. When including predicted lost productivity due to CRS, the average discounted direct and indirect lifetime costs per surviving CRS patient amounted to US$ 98,734.

Item Type: Article
Faculty and Department: Faculty of Public Health and Policy > Dept of Global Health and Development
Research Centre: Centre for Global Non-Communicable Diseases (NCDs)
Vaccine Centre
PubMed ID: 16814433
Web of Science ID: 241178400009
URI: http://researchonline.lshtm.ac.uk/id/eprint/11404

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
304Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item